Business Context and Reporting Period
This Form 8-K reports on the results of the 2026 Annual Meeting of Stockholders held by Zentalis Pharmaceuticals, Inc. on June 16, 2026. The filing details the voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 49,453,766 shares were present or represented by proxy, representing approximately 69.47% of outstanding common stock. The following proposals were approved:
- Item 1 (Director Election): David Johnson and Jan Skvarka, Ph.D., were elected as Class III Directors to serve until the 2029 Annual Meeting.
- Item 2 (Auditor Ratification): The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.
- Item 3 (Executive Compensation): The advisory approval of the compensation of the Company's named executive officers was passed.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the specific vote counts for the advisory executive compensation proposal (Item 3), which received significant "Against" votes (10,930,673) compared to "For" votes (21,949,844).
- Confirm the tenure of the newly elected Class III Directors (David Johnson and Jan Skvarka, Ph.D.) extends through the 2029 Annual Meeting.
- Review the definitive proxy statement filed on April 30, 2026, for detailed background on the proposals.